Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Terminated(1)

Detailed Status

Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

active_not_recruiting150%
withdrawn150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingphase_1

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

NCT02192359
withdrawnphase_1

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

NCT02055196

Clinical Trials (2)

Showing 2 of 2 trials
NCT02192359Phase 1

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Active Not Recruiting
NCT02055196Phase 1

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2